Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Studies and Practice

Pharmaceutical utilisation and costs before and after bariatric surgery

International Journal of Obesity volume 37, pages 1467–1472 (2013)Cite this article

Subjects

Abstract

Objective:

To determine whether pharmaceutical utilisation and costs change after bariatric surgery.

Subjects:

Total population of Australians receiving Medicare-subsidised laparoscopic adjustable gastric banding (LAGB) in 2007 (n=9542).

Design:

Computerised data linkage with Medicare, Australia’s universal tax-funded health insurance scheme. Pharmaceuticals relating to obesity-related disease and postsurgical management were assigned to therapeutic categories and analysed. The mean annual numbers of pharmaceutical prescriptions for each category were compared over the 4-year period from the year before LAGB (2006) to 2 years after LAGB (2009) using utilisation incidence rate ratios (IRRs).

Results:

The population was mainly female (77.7%) and age was normally distributed with the majority (60.7%) of subjects aged between 35–54 years. Utilisation rates decreased significantly after LAGB in the following therapeutic categories: diabetes (IRR 0.51, IRR 95% CI 0.50–0.53, mean annual cost differences per person $30), cardiovascular (0.81, 0.80–0.82, $29), psychiatric (0.95, 0.93–0.97, $13), rheumatic and inflammatory disorders (0.51, 0.49–0.53, $10) and asthma (0.78, 0.75–0.81, $9). In contrast, significantly greater utilisation was observed in the pain (1.28, 1.23–1.32, $12), gastrointestinal tract disorder (1.04, 1.02–1.07, $5) and anaemia/vitamins (2.34, 2.01–2.73, $4) therapeutic categories. When the defined categories were combined, a net reduction in pharmaceutical utilisation was observed, from 10.5 to 9.6 pharmaceuticals prescribed per person/year, and costs decreased from $AUD517 to $AUD435 per year in 2009 prices.

Conclusion:

Relative to the year before LAGB, overall pharmaceutical utilisation was reduced in the 2 years after the year of LAGB surgery, demonstrating that bariatric surgery can lead to reductions in pharmaceutical utilisation in the ‘real world’ setting. The greatest absolute cost reductions were observed in the therapies to treat diabetes and cardiovascular disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Walls HL, Wolfe R, Haby MM, Magliano DJ, de Courten M, Reid CM et al. Trends in BMI of urban Australian adults, 1980-2000. Public Health Nutr 2010; 13: 631–638.

    Article  Google Scholar 

  2. Freedman DS, Khan LK, Serdula MK, Galuska DA, Dietz WH . Trends and correlates of class 3 obesity in the United States from 1990 through 2000. JAMA 2002; 288: 1758–1761.

    Article  Google Scholar 

  3. Neovius M, Teixeira-Pinto A, Rasmussen F . Shift in the composition of obesity in young adult men in Sweden over a third of a century. Int J Obes 2008; 32: 832–836.

    Article  CAS  Google Scholar 

  4. Hensrud DD, Klein S . Extreme obesity: a new medical crisis in the United States. Mayo Clin Proc 2006; 81: S5–10.

    Article  Google Scholar 

  5. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH . The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523–1529.

    Article  CAS  Google Scholar 

  6. Colditz GA, Willett WC, Rotnitzky A, Manson JE . Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481–486.

    Article  CAS  Google Scholar 

  7. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC . Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17: 961–969.

    Article  CAS  Google Scholar 

  8. Glenny AM, O’Meara S, Melville A, Sheldon TA, Wilson C . The treatment and prevention of obesity: a systematic review of the literature. Int J Obes Relat Metab Disord 1997; 21: 715–737.

    Article  CAS  Google Scholar 

  9. Norris SL, Zhang X, Avenell A, Gregg E, Brown TJ, Schmid CH et al. Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev 2005; CD004095.

  10. Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugerman HJ, Livingston EH et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med. 2005; 142: 547–559.

    Article  Google Scholar 

  11. O’Brien PE, Brown WA, Dixon JB . Obesity, weight loss and bariatric surgery. Med J Aust 2005; 183: 310–314.

    PubMed  Google Scholar 

  12. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683–2693.

    Article  Google Scholar 

  13. Dixon JB, O’Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008; 299: 316–323.

    CAS  Google Scholar 

  14. Sjostrom L, Peltonen M, Jacobson P, Sjostrom CD, Karason K, Wedel H et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56–65.

    Article  Google Scholar 

  15. Sjostrom L, Gummesson A, Sjostrom CD, Narbro K, Peltonen M, Wedel H et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol 2009; 10: 653–662.

    Article  Google Scholar 

  16. Karlsson J, Taft C, Ryden A, Sjostrom L, Sullivan M . Ten-year trends in health-related quality of life after surgical and conventional treatment for severe obesity: the SOS intervention study. Int J Obes 2007; 31: 1248–1261.

    Article  CAS  Google Scholar 

  17. Dixon JB, Dixon ME, O’Brien PE . Depression in association with severe obesity: changes with weight loss. Arch Intern Med 2003; 163: 2058–2065.

    Article  Google Scholar 

  18. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741–752.

    Article  Google Scholar 

  19. Australian Government Department of Health and Ageing. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee—December 2008. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbacguidelines-index . Accessed May 5, 2010.

  20. Siegel JE, Weinstein MC, Russell LB, Gold MR . Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1339–1341.

    Article  CAS  Google Scholar 

  21. nited Kingdom National Institute for Clinical Excellence. NICE guidelines: Incorporating health economics in guidelines and assessing resource impact. UAvailable from: http://www.nice.org.uk/niceMedia/pdf/GuidelinesManualChapter8.pdf. [Accessed May 13 2010].

  22. Snow LL, Weinstein LS, Hannon JK, Lane DR, Ringold FG, Hansen PA et al. The effect of Roux-en-Y gastric bypass on prescription drug costs. Obes Surg 2004; 14: 1031–1035.

    Article  Google Scholar 

  23. Segato G, Busetto L, De Luca M, De Stefano F, Marangon M, Salvalaio S et al. Weight loss and changes in use of antidiabetic medication in obese type 2 diabetics after laparoscopic gastric banding. Surg Obes Relat Dis 2010; 6: 132–137.

    Article  Google Scholar 

  24. Potteiger CE, Paragi PR, Inverso NA, Still C, Reed MJ, Strodel W et al. Bariatric surgery: shedding the monetary weight of prescription costs in the managed care arena. Obes Surg 2004; 14: 725–730.

    Article  Google Scholar 

  25. Nguyen NT, Varela JE, Sabio A, Naim J, Stamos M, Wilson SE . Reduction in prescription medication costs after laparoscopic gastric bypass. Am Surg 2006; 72: 853–856.

    PubMed  Google Scholar 

  26. Monk JS, Dia Nagib N, Stehr W . Pharmaceutical savings after gastric bypass surgery. Obes Surg 2004; 14: 13–15.

    Article  Google Scholar 

  27. Malone M, Alger-Mayer SA . Medication use patterns after gastric bypass surgery for weight management. Ann Pharmacother 2005; 39: 637–642.

    Article  Google Scholar 

  28. Makary MA, Clarke JM, Shore AD, Magnuson TH, Richards T, Bass EB et al. Medication utilization and annual health care costs in patients with type 2 diabetes mellitus before and after bariatric surgery. Arch Surg 2010; 145: 726–731.

    Article  Google Scholar 

  29. Gould JC, Garren MJ, Starling JR . Laparoscopic gastric bypass results in decreased prescription medication costs within 6 months. J Gastrointest Surg 2004; 8: 983–987.

    Article  Google Scholar 

  30. Cremieux PY, Ledoux S, Clerici C, Cremieux F, Buessing M . The impact of bariatric surgery on comorbidities and medication use among obese patients. Obes Surg 2010; 20: 861–870.

    Article  Google Scholar 

  31. Narbro K, Agren G, Jonsson E, Naslund I, Sjostrom L, Peltonen M . Pharmaceutical costs in obese individuals: comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: the SOS intervention study. Arch Intern Med 2002; 162: 2061–2069.

    Article  Google Scholar 

  32. Buchwald H, Oien DM . Metabolic/bariatric surgery Worldwide 2008. Obes Surg 2009; 19: 1605–1611.

    Article  Google Scholar 

  33. Australian Department of Health and Ageing. Items for the surgical treatment of obesity. 2011; Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/7C0B7F27D7F739B5CA25782A00821F3F/$File/DRAFT%20obesity%20report.pdf . Accessed 15 May, 2012.

  34. Australian Department of Health and Ageing. Pharmaceutical Benefits Schedule online. Available at http://www.pbs.gov.au/pbs/home . Accessed 11 May, 2011.

  35. World Health Organisation. Collaborating Centre for Drug Statistics Methodology. Available at www.whocc.no/ . Accessed 5 June 2011.

  36. Armitage P, Berry G, Matthews JNS . Statistical Methods in Medical Research 4th ed. Blackwell: Malden, MA, 2002.

    Book  Google Scholar 

  37. Australian Institute of Health and Welfare. Health expenditure Australia 2008–09. Available from: http://www.aihw.gov.au/workarea/downloadasset.aspx?id=6442472701 . Accessed 18 May 2012.

  38. Dixon JB, Murphy DK, Segel JE, Finkelstein EA . Impact of laparoscopic adjustable gastric banding on type 2 diabetes. Obes Rev 2012; 13: 57–67.

    Article  CAS  Google Scholar 

  39. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 1724–1737.

    Article  CAS  Google Scholar 

  40. Simard B, Turcotte H, Marceau P, Biron S, Hould FS, Lebel S et al. Asthma and sleep apnea in patients with morbid obesity: outcome after bariatric surgery. Obes Surg 2004; 14: 1381–1388.

    Article  Google Scholar 

  41. Hooper MM, Stellato TA, Hallowell PT, Seitz BA, Moskowitz RW . Musculoskeletal findings in obese subjects before and after weight loss following bariatric surgery. Int J Obes 2007; 31: 114–120.

    Article  CAS  Google Scholar 

  42. Dixon JB, Chapman L, O’Brien P . Marked improvement in asthma after Lap-Band surgery for morbid obesity. Obes Surg 1999; 9: 385–389.

    Article  CAS  Google Scholar 

  43. Herpertz S, Kielmann R, Wolf AM, Langkafel M, Senf W, Hebebrand J . Does obesity surgery improve psychosocial functioning? A systematic review. Int J Obes Relat Metab Disord 2003; 27: 1300–1314.

    Article  CAS  Google Scholar 

  44. Kolotkin RL, Crosby RD, Gress RE, Hunt SC, Adams TD . Two-year changes in health-related quality of life in gastric bypass patients compared with severely obese controls. Surg Obes Relat Dis 2009; 5: 250–256.

    Article  Google Scholar 

  45. Nickel MK, Loew TH, Bachler E . Change in mental symptoms in extreme obesity patients after gastric banding, Part II: Six-year follow up. Int J Psychiatry Med 2007; 37: 69–79.

    Article  CAS  Google Scholar 

  46. Sarwer DB, Fabricatore AN, Jones-Corneille LR, Allison KC, Faulconbridge LN, Wadden TA . Psychological issues following bariatric surgery. Primary Psychiatry 2008; 15: 50–55.

    Google Scholar 

  47. Schowalter M, Benecke A, Lager C, Heimbucher J, Bueter M, Thalheimer A et al. Changes in depression following gastric banding: a 5–7-year prospective study. Obes Surg 2008; 18: 314–320.

    Article  Google Scholar 

  48. Christou NV, Sampalis JS, Liberman M, Look D, Auger S, McLean AP et al. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg 2004; 240: 416–423 discussion 23–4.

    Article  Google Scholar 

  49. Cremieux PY, Ledoux S, Clerici C, Cremieux F, Buessing M . The impact of bariatric surgery on comorbidities and medication use among obese patients. Obes Surg. Jul 20: 861–870.

    Article  Google Scholar 

  50. Neovius M, Narbro K, Keating C, Peltonen M, Sjoholm K, Agren G et al. Health care use during 20 years following bariatric surgery. JAMA 2012; 308: 1132–1141.

    Article  CAS  Google Scholar 

  51. Sampalis JS, Liberman M, Auger S, Christou NV . The impact of weight reduction surgery on health-care costs in morbidly obese patients. Obes Surg 2004; 14: 939–947.

    Article  Google Scholar 

  52. Segal JB, Clark JM, Shore AD, Dominici F, Magnuson T, Richards TM et al. Prompt reduction in use of medications for comorbid conditions after bariatric surgery. Obes Surg 2009; 19: 1646–1656.

    Article  Google Scholar 

  53. Mechanick JI, Kushner RF, Sugerman HJ, Gonzalez-Campoy JM, Collazo-Clavell ML, Spitz AF et al. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Obesity 2009; 17: S1–70 v.

    Article  Google Scholar 

  54. Dixon JB, Reuben Y, Halket C, O’Brien PE . Shoulder pain is a common problem following laparoscopic adjustable gastric band surgery. Obes Surg 2005; 15: 1111–1117.

    Article  Google Scholar 

  55. Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 2009; 13: 1–190 215-357, iii-iv.

    Article  CAS  Google Scholar 

  56. Salem L, Devlin A, Sullivan SD, Flum DR . Cost-effectiveness analysis of laparoscopic gastric bypass, adjustable gastric banding, and nonoperative weight loss interventions. Surg Obes Relat Dis 2008; 4: 26–32.

    Article  Google Scholar 

  57. Abdullah A, Stoelwinder J, Shortreed S, Wolfe R, Stevenson C, Walls H et al. The duration of obesity and the risk of type 2 diabetes. Public Health Nutr 2011; 14: 119–126.

    Article  Google Scholar 

  58. Abdullah A, Wolfe R, Stoelwinder JU, de Courten M, Stevenson C, Walls HL et al. The number of years lived with obesity and the risk of all-cause and cause-specific mortality. Int J Epidemiol 2011; 40: 985–996.

    Article  Google Scholar 

  59. Finkelstein EA, Allaire BT, Burgess SM, Hale BC . Financial implications of coverage for laparoscopic adjustable gastric banding. Surg Obes Relat Dis 2011; 7: 295–303.

    Article  Google Scholar 

  60. Australian Department of Health and Ageing. Clinical Practice Guidelines for the Management of Overweight and Obesity in Adults http://www.health.gov.au/internet/main/publishing.nsf/Content/obesityguidelinesguidelines-adults.htm . Accessed 2 January, 2011.

  61. Fried M, Hainer V, Basdevant A, Buchwald H, Deitel M, Finer N et al. Inter-disciplinary European guidelines on surgery of severe obesity. Int J Obes 2007; 31: 569–577.

    Article  CAS  Google Scholar 

  62. Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr 1992; 55: 615S–619SS.

  63. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122: 248–56 e5.

    Article  Google Scholar 

  64. Alemayehu B, Warner KE . The lifetime distribution of health care costs. Health Serv Res 2004; 39: 627–642.

    Article  Google Scholar 

  65. Kraja AT, Borecki IB, North K, Tang W, Myers RH, Hopkins PN et al. Longitudinal and age trends of metabolic syndrome and its risk factors: the Family Heart Study. Nutr Metab 2006; 3: 41.

    Article  Google Scholar 

Download references

Acknowledgements

We thank Medicare Australia who assisted with the identification of populations analysed in this study and provided detailed pharmaceutical data for each sample. We would also like to thank Prof John Dixon for assistance interpreting selected results and Professor Paul O’Brien for providing mean presurgical BMI data for all patients receiving LAGB surgery at the Centre for Bariatric Surgery (Melbourne) during 2009. CLK had full access to all the data in the study and takes full responsibility for the integrity of the data and accuracy of analysis.

Author information

Authors and Affiliations

  1. Deakin Health Economics, Deakin University, Melbourne, Australia

    C L Keating, R Carter & M L Moodie

  2. Obesity and Population Health, Baker IDI Heart and Diabetes Institute, Melbourne, Australia

    A Peeters

  3. World Health Organisation Collaborating Centre for Obesity Prevention, Deakin University, Melbourne, Australia

    B A Swinburn

Authors
  1. C L Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Peeters
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B A Swinburn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M L Moodie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C L Keating.

Ethics declarations

Competing interests

AP is funded by VicHealth, NHMRC and ARC, and has also received research funds from the Global Corporate Challenge. CLK and MLM received an independent research grant from Allergan Australia. Allergan played no part in the design of the study, collection or analysis of the data. BAS and RC declare no potential conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keating, C., Peeters, A., Swinburn, B. et al. Pharmaceutical utilisation and costs before and after bariatric surgery. Int J Obes 37, 1467–1472 (2013). https://doi.org/10.1038/ijo.2013.24

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijo.2013.24

Keywords

This article is cited by

Search

Advanced search

Quick links